New pill VENT-03 aims to calm lupus skin flares
NCT ID NCT07260877
First seen Jan 08, 2026
Summary
This study tests whether VENT-03, a tablet, can reduce skin inflammation in people with active cutaneous lupus (with or without systemic lupus). 24 adults will take VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researchers will check skin severity and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigative Site
RECRUITINGBeverly Hills, California, 90211, United States
-
Investigative Site
RECRUITINGClearwater, Florida, 33765, United States
-
Investigative Site
RECRUITINGDeBary, Florida, 32713, United States
-
Investigative Site
RECRUITINGTampa, Florida, 33606, United States
-
Investigative Site
RECRUITINGSaint Joseph, Missouri, 64506, United States
-
Investigative Site
RECRUITINGFairport, New York, 14450, United States
-
Investigative Site
RECRUITINGMemphis, Tennessee, 38119, United States
-
Investigative Site
RECRUITINGAllen, Texas, 75013, United States
-
Investigative Site
RECRUITINGArlington, Texas, 76012, United States
-
Investigative Site
RECRUITINGColleyville, Texas, 76034, United States
-
Investigative Site
RECRUITINGHaskovo, Bulgaria
-
Investigative Site
RECRUITINGPlovdiv, Bulgaria
-
Investigative Site
RECRUITINGSofia, Bulgaria
-
Investigative Site
RECRUITINGParis, France
-
Investigative Site
RECRUITINGToulouse, France
-
Investigative Site
RECRUITINGTbilisi, Georgia
-
Investigative Site
RECRUITINGSzeged, Hungary
-
Investigative Site
RECRUITINGBialystok, Poland
-
Investigative Site
RECRUITINGOświęcim, Poland
-
Investigative Site
RECRUITINGPoznan, Poland
-
Investigative Site
RECRUITINGRzeszów, Poland
-
Investigative Site
RECRUITINGŚląskie, Poland
-
Investigative Site
RECRUITINGWarsaw, Poland
-
Investigative Site
RECRUITINGWroclaw, Poland
-
Investigative Site
RECRUITINGPretoria, South Africa
-
Investigative Site
RECRUITINGStellenbosch, South Africa
-
Investigative Site
RECRUITINGBadajoz, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VENT-03 (a tablet)
What this could lead to
If it works, this could point toward a new treatment option for people with cutaneous lupus, reducing skin inflammation and severity.
What could go wrong
This is a very early, small Phase 2a trial with only 24 participants. The drug may not prove effective or may cause side effects. Results may not apply to all lupus patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.